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uate higher their satisfaction from price adequacy. CONCLU-
SIONS: The evaluation of users’ satisfaction from medication as
well as the determination of the factors affecting it should be
incorporated into the third party payers, the pharmaceutical
industry and the Greek government decision making.
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OBJECTIVE: Many Medicare enrolled veterans view the
Department of Veterans Affairs (VA) as a preferred source of
pharmacy services, even when they have access to pharmacy cov-
erage elsewhere. With the implementation of the Medicare phar-
macy beneﬁt imminent, the objective of these analyses was to
examine how one alternative source of pharmacy care, Medicare
managed care (HMO) enrollment, affects the use of VA phar-
macy services. METHODS: We combined national calendar year
(CY) 2002 Medicare enrollment data for Medicare-enrolled VA
users with pharmacy cost records from the VA’s national Deci-
sion Support System (DSS) ﬁles. VA users were identiﬁed as a
Medicare HMO enrollee if they were enrolled in a Medicare
HMO at any time during CY 2002. RESULTS: In CY 2002, 2.3
million Medicare enrolled veterans (5.4% of all Medicare bene-
ﬁciaries) received medications from the VA, at a total cost of $2.4
billion (68% of all VA pharmacy costs). Across the 127 individ-
ual VA medical centers (VAMCs) there was wide variation in the
percentage of HMO enrollees among Medicare enrolled phar-
macy users (from <1% to >49%) and in the percentage of phar-
macy costs associated with their use (from <1% to >41%). HMO
enrollees were just as likely as non-enrollees to use VA pharmacy
care, although the average annual cost of their care was lower—
$847 per year [sd = $1969] versus $1101 [$2794] for non-
enrollees (p £ 0.0001). CONCLUSIONS: VA users who are
enrolled in Medicare HMOs continue to use VA pharmacy ser-
vices, even though the large majority of them have access to
pharmacy coverage through their HMO plans. Although the
implementation of the Medicare prescription drug beneﬁt in
2006 is expected to increase access to prescription drugs for
Medicare beneﬁciaries, the VA will likely remain a signiﬁcant
pharmacy provider for Medicare enrolled veterans.
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OBJECTIVES: To provide a comprehensive and systematic
review of the literature on medical tourism and health tourism,
to present a grounded conceptual model for the constructs and
to provide a historical background on the matter. METHODS:
“Medical tourism” and “health tourism” were separately
searched using the Medline database to review the literature on
the availability and use of the terms. Given the limited results
for both terms, the broader term “tourism” was searched.
Entries referring to a type of tourism were investigated further
for classiﬁcation of the variants of tourism and to understand
their nature and context of use in the ﬁeld. RESULTS: The
Medline search for “medical tourism” generated only nine
results while the term “health tourism” produced 15 results. The
term “tourism” produced 445 entries 177 of which were non-
English; all languages were considered in the abstract review. Of
the 445 entries, 58 types of tourism and four categories were
generated with “well-being” as main reference for the grounded
conceptual model. Analysis of the results revealed that an explicit
deﬁnition for either term is the exception rather than the rule
and that the two terms are treated as similar concepts. CON-
CLUSION: The review of the literature underlined the problem
of a severely limited literature and the lack of consensus on def-
initions and clarity on the conceptual framework. This paper
deﬁned health tourism as travel outside one’s local environment
for the maintenance, improvement or restoration of the individ-
ual’s well-being in mind and body while medical tourism, a
subset of the health tourism is travel outside one’s natural health
care jurisdiction for the improvement or restoration of the indi-
vidual’s well-being in mind and body. This overview has pre-
sented that as a matter of history, the concept of health tourism
and medical tourism is not new.
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OBJECTIVES: Governmental price regulation of drugs has
become a popular measure to contain health care spending. The
aim is to evaluate the effectiveness of selected demand and supply
side measures, keeping in mind crucial factors in this market, for
instance the free rider problem and moral hazard. METHODS:
To analyze reference price limits on reimbursement a static two
class product model is introduced. Beside this measure addi-
tionally patents, parallel imports as supply side price regulation
and drug budget for physicians and generic drugs as demand side
price regulation will be reviewed. RESULTS: By using a sequen-
tial price-setting process within the model it can be shown that
applying marginal cost pricing for drugs clustered within Phase
1, welfare can be increased. If government sets the reference price
equal to the marginal costs welfare can be increased without free
riding on the sunk R&D costs of researching pharmaceutical
ﬁrms because the patent protection has expired. To give a com-
prehensive evaluation of the other pricing policies the interac-
tions between regulative measures are taken into account.
CONCLUSIONS: In the past too many regulative measures to
contain health care expenditures have been targeted primarily to
supply side measures or to demand side measures. But, regula-
tion that only applies on one side does little to control the rising
expenditures. Without simultaneous use of demand side incen-
tives and volume controls, pharmaceutical expenditures proba-
bly can not be reduced effectively.
PHP13
MULTIPLE APPRAISAL OF DRUGS IN THE UK HEALTH 
CARE SYSTEM
Hutton J1, Pang F2
1United BioSource Corporation, London, UK; 2Abbott Laboratories
Ltd, Maidenhead, Berkshire, UK
OBJECTIVES: To review the three national bodies responsible
for health technology assessment in the UK: the National Insti-
tute for Health and Clinical Excellence (NICE), the Scottish
Medicines Consortium (SMC) and the All Wales Medicines Strat-
egy Group (AWMSG); to judge their ﬁtness for purpose; and to
assess the value of a multi-layered system. METHODS: The
working of the organisations was classiﬁed under four headings:
objectives and scope; assessment of technologies; the decision
process; implementation. The main source of information was
the documentation produced by these bodies on their rules,
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processes and decisions. The health economics and health policy
literature was reviewed for commentaries and case studies of par-
ticular decisions. Where decisions had been made by different
bodies on the same technology those were reviewed for consis-
tency. Parallels were drawn with methods of regulating market
access in other European countries. RESULTS: NICE procedures
were the most thorough but could not be applied early or to all
technologies because of their resource- intensive nature. Method-
ological expectations for company submissions were similar
between organisations, but the degree of independent review
varied with the annual number of technologies assessed. In 
most cases, NICE and SMC decisions on the same drug were
consistent. SMC most resembled equivalent systems in other
European countries by evaluating drugs at launch. AWMSG was
most concerned with budget impact. CONCLUSIONS: Most dif-
ferences between the organisations could be explained by their
differing objectives, scope of activities and timing of their inter-
vention. The SMC was more concerned with timely and com-
prehensive coverage of all drugs, reﬂecting its closer links to
NHS. NICE was only beginning to address implementation.
Properly co-coordinated, the sequence of evaluations could
follow a logical development of evidence quality over time, with
minimal redundant work on company submissions. Without
such co-ordination a waste of valuable time and resources is
likely.
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OBJECTIVE: The Medicare Prescription Drug, Improvement
and Modernization Act (MMA) of 2003 directed the Medicare
Payment Advisory Commission (MedPAC) to conduct a study of
hospital pharmacy handling costs. The June 2005 MedPAC
report recommended payment for handling costs of Part B spec-
iﬁed outpatient drugs based on submitted charges, reduced to
costs. This study explores policy implications of MedPAC rec-
ommendations concerning potential OPPS pharmacy handling
cost payment methodology. METHODS: Various methods of
recording charges for pharmacy services were collected from a
hospital survey of systems (n = 399) and categorized. Past CMS
and MedPAC discussions of pharmacy costs and charges were
identiﬁed and accumulated in an indexed database. Findings
from the hospital sources and the governmental sources were
compared and underlying assumptions examined with a view
toward predicting 2006 CMS approaches to determining hospi-
tal pharmacy handling cost payment. RESULTS: The hospital
survey revealed signiﬁcant variation in whether hospital phar-
macy department drug charges recognize overhead such as han-
dling costs. Forty-three percent of survey respondents did include
such a charge. Types of charges reported were for dispensing
(35%), compounding (25%), a combination of dispensing and
compounding (23%) and all other (17%). When entries in the
indexed database of CMS and MedPAC discussions of pharmacy
costs and charges were compared to the hospital responses about
actual departmental cost and charge methods currently in use,
analyses revealed a signiﬁcant differential between methods
reported by hospital respondents (including charge compression)
and methods discussed in published CMS and MedPAC sources.
CONCLUSIONS: Future payment rates for hospital pharmacy
handling costs will likely be derived from hospital submitted
charges, per the MedPAC recommendation. If the payment
methodology does not take existing variations of recording phar-
macy costs and charges into account, the resulting method will
be signiﬁcantly ﬂawed and hospital providers may ﬁnd they are
underpaid for pharmacy handling costs in 2006.
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OBJECTIVES: The Spanish Agency of Medicines and Health
care Products (SAMHP) makes regulatory decisions concerning
pharmacovigilance. Here, we analyse the impact of actions
related to safety adopted by the SAMHP on drug consumption
ﬁnanced by the Spanish National Health System (NHS), over the
period 1990–2004. METHODS: A retrospective analysis of the
consumption was made, selecting drugs which were eventually
withdrawn from the market. Consumption data was provided
by the Ministry of Health and Consume (MHC) database and
expressed as number of prescriptions. Drugs selected were 
classiﬁed according to type of Adverse Drug Reaction (ADR),
Anatomic Therapeutic-Chemical Classiﬁcation (ATC) and degree
of therapeutic innovation at the moment of authorisation,
according to the MHC. RESULTS: Fourteen drugs were selected
for the purpose of this study, and none of these were categorised
as “an exceptional therapeutic novelty”. The most common
ADRs concerned severe liver (7/14) or heart (5/7) toxicity. At
least 8 of the 14 drugs were associated with one safety action
before being withdrawn. This was either a product labeling 
modiﬁcation (astemizole, droxicam, nimesulide, nefazodone,
cerivastatine, trovaﬂoxacine, and rofecoxib) or classiﬁcation as
hospitalary diagnostic (cisapride). Rofecoxib was the only one
with two actions. A high level of consumption and in a very short
time from authorisation until the ﬁrst safety action (between one
to three years) was found in nimesulide, cerivastatine and rofe-
coxib. In the rest of the drugs, the only action was the with-
drawn. This happened after one year post-authorisation
(tolcapone, sertindol, and grepaﬂoxacine) or in the case of ebro-
tidine, two years. CONCLUSIONS: The drugs withdrawn after
one or two years from their authorisation would seem reason-
able not have been ﬁnanced by NHS. In all drugs, the ﬁrst safety
action resulted in a signiﬁcant decrease in consumption. In some
of these cases, manufacturers requested to SAMHP drug to be
withdrawn.
PHP16
ESTIMATING THE COST SAVINGS AND RATIONAL USE
EFFECTS OF IMPLEMENTING AN ESSENTIAL MEDICINES LIST
Hamidi S1, Khan M1, Babo D1, Culbertson R1, Rice J1,Younis M2
1Tulane University, New Orleans, LA, USA; 2Jackson State University,
Jackson, MS, USA
OBJECTIVES: To determine the effects of implementing essen-
tial medicines list on rational use of medicines and medicine cost
savings in the public sector of West Bank, Palestine. METHODS:
The effect of EML on medicine expenditure was divided into two
separate components: the effect of EML on quantities used, and
the effect on medicine prices. The quantities of 76 medicine
groups were used as the dependent variable with real GDP per
capita, EML dummy, hospital dummy, time, and percent of
insured population, as independent variables. Another set of
regressions were deﬁned with real medicine price per deﬁned
daily dose as dependent variable and real GDP per capita, EML,
and percent insured as independent variables. A sample of pre-
scriptions was also analyzed to measure the indices of rational
medicine use. The indicators of rational use of medicines were
assumed to be a function of EML, and 16 health center dummy
